C. Fiévet

发表

Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine.

B. Staels, J. Fruchart, C. Duval, 2006, Biochemical and biophysical research communications.

Peroxisome Proliferator-activated Receptor-α Regulates Lipid Homeostasis, but Is Not Associated with Obesity

J. Auwerx, J. Ward, C. Nicol, 2001, The Journal of Biological Chemistry.

Intestinal ABCA1 directly contributes to HDL biogenesis in vivo.

Albert K Groen, Folkert Kuipers, M. Hayden, 2006, The Journal of clinical investigation.

Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.

B. Staels, C. Fiévet, C. Fiévet, 2009, Biochemical pharmacology.

Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.

J. Seckl, J. Mullins, B. Staels, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Relation of Arteriographically Defined Coronary Artery Disease to Serum Lipoprotein Particles Mapped With Monoclonal Antibodies

M. C. Nuttens, P. Ducimetiere, J. Fruchart, 1991, Circulation.

3‐Hydroxy‐3‐methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C‐III and lipoprotein lipase

J. Auwerx, K. Schoonjans, J. Fruchart, 1999, FEBS letters.

Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits.

P. Denéfle, L. Houdebine, J. Caillaud, 1996, Circulation.

The Liver-Selective Thyromimetic T-0681 Influences Reverse Cholesterol Transport and Atherosclerosis Development in Mice

M. Rudling, C. Fiévet, J. Patsch, 2010, PloS one.

Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5'-triphosphate-binding cassette transporter 1 expression.

M. Rudling, C. Fiévet, J. Patsch, 2008, Endocrinology.

Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.

J. Caillaud, J. Fruchart, A. Tailleux, 2001, Clinical science.

Immunological and functional properties of in vitro oxidized low density lipoprotein.

J. Fruchart, A. Tailleux, C. Fiévet, 1995, Journal of lipid research.

Immunological properties of apoB-containing lipoprotein particles in human atherosclerotic arteries.

G. Torpier, J. Fruchart, A. Tailleux, 1993, Journal of lipid research.

17β-Estradiol Prevents Fatty Streak Formation in Apolipoprotein E–Deficient Mice

J. Arnal, J. Faye, C. Fiévet, 1997 .

Modulation of the expression of human LDL-Apo B-100 epitopes by lipids and apolipoproteins.

J. Fruchart, A. Tailleux, C. Fiévet, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.

B. Staels, J. Fruchart, C. Fiévet, 2006, Current opinion in pharmacology.

Distribution of apolipoprotein E between apo B- and non apo B-containing lipoproteins according to apo E phenotype.

D. Arveiler, G. Luc, F. Cambien, 1997, Atherosclerosis.

Combination therapy of statins and fibrates in the management of cardiovascular risk

B. Staels, C. Fiévet, 2009, Current opinion in lipidology.

Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients.

J. Fruchart, T. Crea, B. Guerci, 1996, Metabolism: clinical and experimental.

Expression of apolipoprotein B epitopes in low density lipoproteins of hemodialyzed patients.

J. Fruchart, A. Tailleux, C. Fiévet, 1993, Kidney international.

Reduction of Atherosclerosis by the Peroxisome Proliferator-activated Receptor α Agonist Fenofibrate in Mice*

Y. Chao, S. Wright, A. Tedgui, 2002, The Journal of Biological Chemistry.

Apolipoprotein A-I-Containing Particles and Reverse Cholesterol Transport in IDDM

P. Duchateau, J. Fruchart, P. Drouin, 1992, Diabetes.

Human Apolipoprotein A-II Determines Plasma Triglycerides by Regulating Lipoprotein Lipase Activity and High-Density Lipoprotein Proteome

N. Rotllan, C. de la Torre, C. Fiévet, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Decreased Susceptibility to Diet-Induced Atherosclerosis in Human Apolipoprotein A-II Transgenic Mice

G. Luc, J. Caillaud, J. Fruchart, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport.

E. Rubin, P. Denéfle, J. Fruchart, 1997, Biochemistry.

Increased triglyceride levels in shift workers.

M. Romon, J. Fruchart, C. Fiévet, 1992, The American journal of medicine.

Quantitation of human serum apolipoprotein B by enzyme immunoassay in excess antigen.

J. Fruchart, C. Fiévet, A. Dedieu, 1986, Clinica chimica acta; international journal of clinical chemistry.

HDL heterogeneity and coronary heart disease.

J. Fruchart, C. Fiévet, 1991, Diabetes/metabolism reviews.

Cholesterol 7&agr;-Hydroxylase Deficiency in Mice on an APOE*3-Leiden Background Increases Hepatic ABCA1 mRNA Expression and HDL-Cholesterol

G. Luc, B. Staels, C. Fiévet, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Increases Hepatic ABCA 1 mRNA Expression and HDL-Cholesterol-Hydroxylase Deficiency in Mice on an APOE * 3-Leiden

G. Luc, B. Staels, C. Fiévet, 2006 .

Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate*

G. Luc, A. Tall, L. Lagrost, 2001, The Journal of Biological Chemistry.

Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia

B. Staels, J. Fruchart, C. Fiévet, 2008, Circulation research.

Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis

B. McManus, M. Hayden, M. Pouladi, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Quantification of apolipoprotein C-III in serum by a noncompetitive immunoenzymometric assay.

C. Fiévet, V. Clavey, P. Duriez, 1985, Clinical chemistry.

Activation of PPARdelta alters lipid metabolism in db/db mice.

J. Auwerx, M. D. Leibowitz, D. Moller, 2000, FEBS letters.

Development of a radial immunodiffusion technique employing monoclonal antibodies for apolipoprotein B determination in human plasma.

J. Fruchart, S. Marcovina, C. Fiévet, 1985, Clinica chimica acta; international journal of clinical chemistry.

Enzyme-linked immunoassay on microtitre plates for human apolipoprotein B

S. Marcovina, C. Fiévet, I. Beucler, 1984, La Ricerca in clinica e in laboratorio.

NoncompetitiveEnzyme-LinkedImmunoassayfor ApolipoproteinB in Serum

S. Marcovina, C. Fiévet, J. Fruchart, 1984 .

Genetically-engineered animals as research models for atherosclerosis: their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders.

B. Staels, J. Fruchart, C. Fiévet, 2007, Frontiers in bioscience : a journal and virtual library.

Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor

J. Auwerx, D. Mangelsdorf, J. Repa, 2001, Proceedings of the National Academy of Sciences of the United States of America.

The RXR Agonist Bexarotene Improves Cholesterol Homeostasis and Inhibits Atherosclerosis Progression in a Mouse Model of Mixed Dyslipidemia

B. Staels, F. Kuipers, G. Torpier, 2006, Arteriosclerosis, thrombosis, and vascular biology.

Nondiabetic Mouse Model of Mixed Dyslipidemia , Activators Decrease Macrophage-Laden Atherosclerotic Lesions

G. Torpier, J. Fruchart, A. Tailleux, 2005 .

PPAR&agr;, but not PPAR&ggr;, Activators Decrease Macrophage-Laden Atherosclerotic Lesions in a Nondiabetic Mouse Model of Mixed Dyslipidemia

B. Staels, G. Torpier, J. Fruchart, 2005 .

Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis.

B. Staels, G. Torpier, J. Fruchart, 2003, Trends in pharmacological sciences.

Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta.

D. Lesieur, G. Torpier, J. Fruchart, 2002, Biochemical and biophysical research communications.

Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.

J. Auwerx, B. Staels, J. Fruchart, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Peroxisome Proliferator-Activated Receptor Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective

J. Peters, F. Gonzalez, B. Lefebvre, 2005 .

Branched synthetic peptide constructs mimic cellular binding and efflux of apolipoprotein AI in reconstituted high density lipoproteins.

M. Rosseneu, B. Vanloo, J. Fruchart, 1998, Atherosclerosis.

Subclasses of LpA‐I in coronary artery disease: distribution and cholesterol efflux ability

J. Fruchart, C. Fiévet, B. Derudas, 1997, European journal of clinical investigation.

Transgenic rabbits expressing human apolipoprotein A-I in the liver.

P. Denéfle, B. Laine, J. Fruchart, 1996, Arteriosclerosis, thrombosis, and vascular biology.

EFFECTS OF PPAR γ LIGANDS ON ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE

B. Staels, C. Fiévet, 2006 .

Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates.

G. Luc, R. López-Marure, M. Menjivar, 2009, Clinica chimica acta; international journal of clinical chemistry.

Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription.

E. Raspé, C. Fontaine, B. Staels, 2002, Journal of lipid research.

Identification of Reverb as a physiological repressor of apoC-III gene transcription 1

E. Raspé, C. Fontaine, B. Staels, 2002 .

In vivo glucosylated LpA-I subfraction. Evidence for structural and functional alterations.

C. Slomianny, J. Fruchart, P. Drouin, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Increased plasma levels of LDL cholesterol in rabbits after adenoviral overexpression of human scavenger receptor class B type I

C. Fiévet, J. Patsch, P. Eller, 2005, Journal of Molecular Medicine.

Transcriptional Regulation of Apolipoprotein C-III Gene Expression by the Orphan Nuclear Receptor RORα*

J. Mariani, E. Raspé, B. Staels, 2001, The Journal of Biological Chemistry.

Effect of Fenofibrate on Lipoprotein Particles Predictive of Coronary Atherosclerosis

J. Fruchart, P. Drouin, S. Marcovina, 1987 .

Detection of human apolipoprotein B polymorphic species with one monoclonal antibody (BIP 45) against low density lipoprotein. Influence of this polymorphism on lipid levels and coronary artery stenosis.

P. Fiévet, C. Fiévet, P. Duriez, 1987, Atherosclerosis.

Human Sterol 27-Hydroxylase (CYP27) Overexpressor Transgenic Mouse Model

V. Meiner, B. Staels, C. Fiévet, 2002, The Journal of Biological Chemistry.

Reduced Plasma HDL Cholesterol in Hyperthyroid Mice Coincides with Decreased Hepatic ABCA1 Expression

M. Rudling, C. Fiévet, J. Patsch, 2012 .

Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG 5 / G 8

N. Rotllan, C. Fiévet, F. Blanco-Vaca, 2008 .

Increased Susceptibility of Low-Density Lipoprotein to Ex Vivo Oxidation in Mice Transgenic for Human Apolipoprotein B Treated with 1 Melatonin-Related Compound Is Not Associated with Atherosclerosis Progression

R. Bordet, D. Lesieur, G. Torpier, 2005, Journal of cardiovascular pharmacology.

Interaction of LDL, Lp[a], and reduced Lp[a] with monoclonal antibodies against apoB.

J. Fruchart, S. Marcovina, C. Fiévet, 1988, Journal of lipid research.

Human apolipoprotein B. Evidence for its immunochemical heterogeneity using monoclonal antibodies and an immunoenzymometric assay.

J. Fruchart, C. Fiévet, J. Lecocq, 1988, Clinical biochemistry.

A screening method for abnormally high lipoprotein(a) concentrations by agarose lipoprotein electrophoresis.

J. Fruchart, P. Fiévet, C. Fiévet, 1994, Clinica chimica acta; international journal of clinical chemistry.

Non-enzymatic glycosylation of apolipoprotein A-I and its functional consequences.

J. Fruchart, P. Drouin, C. Fiévet, 1995, Diabete & metabolisme.

The thyromimetic T-0681 protects from atherosclerosis.

B. Foeger, M. Rudling, C. Fiévet, 2009, Journal of lipid research.

Deleting TCR alpha beta+ or CD4+ T lymphocytes leads to opposite effects on site-specific atherosclerosis in female apolipoprotein E-deficient mice.

J. Arnal, P. Gourdy, C. Fiévet, 2004, The American journal of pathology.

Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo

M. Hayden, F. Zimetti, J. Parks, 2006, Circulation.

Measurement of lipoprotein particles.

J. Fruchart, C. Fiévet, 1998, Methods in molecular biology.

Prevention of in vitro low-density lipoprotein oxidation by an albumin-containing Lp A-I subfraction.

J. Fruchart, A. Tailleux, C. Fiévet, 1995, Biochimica et biophysica acta.

Depletion in choline containing phospholipids of LpB particles in adequately controlled type I insulin-dependent diabetes mellitus.

J. Fruchart, P. Drouin, C. Fiévet, 1990, Diabete & metabolisme.

Rexinoid Bexarotene Modulates Triglyceride but not Cholesterol Metabolism via Gene-Specific Permissivity of the RXR/LXR Heterodimer in the Liver

J. Gustafsson, S. Mandrup, T. Pedersen, 2009, Arteriosclerosis, thrombosis, and vascular biology.

PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

B. Staels, J. Fruchart, C. Fiévet, 2006 .

Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis

B. McManus, M. Hayden, J. Parks, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.

J. Flier, B. Walker, J. Seckl, 2004, Diabetes.

The Farnesoid X Receptor Regulates Adipocyte Differentiation and Function by Promoting Peroxisome Proliferator-activated Receptor-γ and Interfering with the Wnt/β-Catenin Pathways*

B. Staels, F. Kuipers, O. Briand, 2010, The Journal of Biological Chemistry.

S 26948

P. Renard, B. Lefebvre, L. Pénicaud, 2007, Diabetes.

Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.

J. Auwerx, B. Staels, J. Fruchart, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Tissue-specific expression of the human gene for lecithin: cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile.

G. Luc, B. Staels, G. Olivecrona, 1995, European journal of biochemistry.

Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle

P. Juvan, S. Horvat, D. Rozman, 2011, BMC Genomics.

Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity.

R. Eckel, J. Auwerx, M. D. Leibowitz, 2001, Molecular pharmacology.

Apo B-containing lipoprotein particles in poorly controlled insulin-dependent diabetes.

C. Slomianny, J. Fruchart, P. Drouin, 1996, Atherosclerosis.

Electroimmuno- and immunonephelometric assays of apolipoprotein A-I by using a mixture of monoclonal antibodies.

J. Fruchart, C. Fiévet, C. Durieux, 1988, Clinical chemistry.

Antibodies of predetermined specificity to apolipoprotein C-II elicited with a synthetic peptide. Characterization and use for immunoassays.

J. Fruchart, C. Fiévet, A. Tartar, 1988, Journal of immunological methods.

Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.

N. Rotllan, X. Palomer, A. Tailleux, 2005, Biochimica et biophysica acta.

Rat monoclonal antibodies to human apolipoprotein B: advantages and applications.

Y. Marcel, H. Bazin, J. Fruchart, 1989, Journal of lipid research.

Chemical approach to synthetic immunogens in clinical chemistry.

J. Fruchart, C. Fiévet, A. Tartar, 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Protective role of interleukin-10 in atherosclerosis.

M. Bureau, V. Deleuze, D. Scherman, 1999, Circulation research.

Krüppel-Like Factor KLF10 Is a Link between the Circadian Clock and Metabolism in Liver

Franck Delaunay, Malayannan Subramaniam, Thomas C. Spelsberg, 2010, Molecular and Cellular Biology.

Human ABCA1 BAC Transgenic Mice Show Increased High Density Lipoprotein Cholesterol and ApoAI-dependent Efflux Stimulated by an Internal Promoter Containing Liver X Receptor Response Elements in Intron 1*

M. Hayden, A. Brooks-Wilson, B. Leavitt, 2001, The Journal of Biological Chemistry.

The atheroprotective effect of 17beta-estradiol depends on complex interactions in adaptive immunity.

G. Hansson, J. Arnal, P. Gourdy, 2005, The American journal of pathology.

Peroxisome Proliferator–Activated Receptor α Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets

F. Pattou, J. Kerr-Conte, B. Staels, 2006, Diabetes.

Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11β-Hydroxysteroid Dehydrogenase Type 1 Null Mice*

John J. Mullins, Megan C. Holmes, J. Seckl, 2001, The Journal of Biological Chemistry.

Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice*

J. Auwerx, J. Peters, F. Gonzalez, 1997, The Journal of Biological Chemistry.

Deleting TCRαβ+ or CD4+ T Lymphocytes Leads to Opposite Effects on Site-Specific Atherosclerosis in Female Apolipoprotein E-Deficient Mice

J. Arnal, P. Gourdy, C. Fiévet, 2004 .

Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator–Activated Receptor &agr; Modulation

G. Luc, J. Peters, F. Gonzalez, 2005, Arteriosclerosis, thrombosis, and vascular biology.

A 700-bp fragment of the human antithrombin III promoter is sufficient to confer high, tissue-specific expression on human apolipoprotein A-II in transgenic mice.

N. Duchange, D. Branellec, J. Fruchart, 1995, Gene.

Systemic Delivery of Murine IL-10 by Intramuscular Injection of Expression Plasmid

V. Deleuze, D. Scherman, M. Bureau, 1999 .

Increased ABCA1 activity protects against atherosclerosis.

B. McManus, M. Hayden, B. Staels, 2002, The Journal of clinical investigation.

Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde.

D. Arveiler, G. Luc, F. Cambien, 1996, Journal of lipid research.

Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease

B. Staels, C. Fiévet, 2009, Current atherosclerosis reports.

Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice Published, JLR Papers in Press, October 24, 2007.

M. Hayden, J. Vance, B. Staels, 2008, Journal of Lipid Research.

Activation of PPARδ alters lipid metabolism in db/db mice

J. Auwerx, M. D. Leibowitz, J. Berger, 2000 .

Noncompetitive enzyme-linked immunoassay for apolipoprotein B in serum.

Y. Moschetto, S. Marcovina, C. Fiévet, 1984, Clinical chemistry.

Complete functional rescue of the ABCA1−/− mouse by human BAC transgenesis Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M400506-JLR200

David J. Arenillas, M. Hayden, W. Wasserman, 2005, Journal of Lipid Research.

Clinical Significance of Lipoprotein Particles

J. Fruchart, C. Fiévet, P. Duriez, 1989 .

Prevention of fatty streak formation of 17beta-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice.

V. Richard, J. Arnal, C. Fiévet, 1997, Circulation.

Effect of fenofibrate treatment on type III hyperlipoproteinemia.

J. Fruchart, C. Fiévet, J. Davignon, 1987, The American journal of medicine.

Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6–11 years): data from a French multicentre retrospective cohort in daily practice

C. Chiaverini, S. Mallet, S. Barbarot, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Hemolysis of erythrocytes by primary pharmacologic agents.

C. Fiévet, H. Ansel, M. Gigandet, 1971, American journal of hospital pharmacy.

Branched synthetic constructs that mimic the physico-chemical properties of apolipoprotein AI in reconstituted high-density lipoproteins.

M. Rosseneu, B. Vanloo, J. Fruchart, 1996, European journal of biochemistry.

Accessibility of human apolipoprotein B-100 epitopes in insulin-dependent diabetes: relation with the surface lipid environment of atherogenic particles.

J. Fruchart, P. Drouin, C. Fiévet, 1996, Diabetes & metabolism.

Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.

L. Madsen, R. Berge, B. Staels, 1999, Circulation.

Loss of atheroprotective effect of estradiol in immunodeficient mice.

G. Getz, J. Arnal, C. Fiévet, 2000, Endocrinology.

17 beta-estradiol prevents fatty streak formation in apolipoprotein E-deficient mice.

J. Arnal, J. Faye, C. Fiévet, 1997, Arteriosclerosis, thrombosis, and vascular biology.

[Circadian meal-related changes in serum lipoprotein levels in normal subjects (author's transl)].

C. Fiévet, S. Moulin, P. Dewailly, 1981, La Nouvelle presse medicale.

Electroimmunoassay for determination of ApoB in human sera by using a mixture of monoclonal antibodies.

J. Fruchart, C. Fiévet, S. Goldstein, 1987, Clinical chemistry.

Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis

B. McManus, M. Pouladi, T. V. van Berkel, 2009, Arteriosclerosis, thrombosis, and vascular biology.

Molecular analysis of atherogenic lipoprotein particles in adequately controlled type I diabetes mellitus.

J. Fruchart, P. Drouin, C. Fiévet, 1988, Advances in experimental medicine and biology.

Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis

B. McManus, M. Hayden, J. Parks, 2009, Arteriosclerosis, Thrombosis and Vascular Biology.

Mapping of lipoprotein particles with monoclonal antibodies in diabetes and atherosclerosis.

J. Fruchart, P. Fiévet, P. Drouin, 1985, Monographs on atherosclerosis.

Molecular analysis of lipoproteins: clinical applications.

J. Fruchart, C. Fiévet, J. Gesquiere, 1987, Advances in experimental medicine and biology.

Atheroprotective Effect of Human Apolipoprotein A5 in a Mouse Model of Mixed Dyslipidemia

B. Staels, J. Fruchart, C. Fiévet, 2008, Circulation research.